HDAC6 and colitis: One of them showed that a potent HDACi, BML-281, suppressed the infiltration of CD19+ B cells into the colonic epithelial cells, and this suppression led to decreased inflammation in the colonic mucosa.70 In the second study, the authors used LTB2 which is an HDAC-6 inhibitor (class II HDAC) as a treatment model in the DSS-induced colitis model in mice.